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New Findings in eNOS gene and 
Thalidomide Embryopathy Suggest 
pre-transcriptional effect variants 
as susceptibility factors
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Maria Teresa Vieira Sanseverino1,2,4, Mara Helena Hutz2, Lavínia Schuler-Faccini1,2,4 & 
Fernanda Sales Luiz Vianna1,2,4,5
Antiangiogenic properties of thalidomide have created an interest in the use of the drug in treatment 
of cancer. However, thalidomide is responsible for thalidomide embryopathy (TE). A lack of knowledge 
regarding the mechanisms of thalidomide teratogenesis acts as a barrier in the aim to synthesize a 
safer analogue of thalidomide. Recently, our group detected a higher frequency of alleles that impair 
the pro-angiogenic mechanisms of endothelial nitric oxide synthase (eNOS), coded by the NOS3 gene. 
In this study we evaluated variable number tandem repeats (VNTR) functional polymorphism in intron 
4 of NOS3 in individuals with TE (38) and Brazilians without congenital anomalies (136). Haplotypes 
were estimated for this VNTR with previously analyzed polymorphisms, rs2070744 (−786C > T) 
and rs1799983 (894T > G), in promoter region and exon 7, respectively. Haplotypic distribution was 
different between the groups (p = 0.007). Alleles −786C (rs2070744) and 4b (VNTR), associated with 
decreased NOS3 expression, presented in higher frequency in TE individuals (p = 0.018; OR = 2.57; 
IC = 1.2–5.8). This association was not identified with polymorphism 894T > G (p = 0.079), which 
influences eNOS enzymatic activity. These results suggest variants in NOS3, with pre-transcriptional 
effects as susceptibility factors, influencing the risk TE development. This finding generates insight for a 
new approach to research that pursues a safer analogue.
The consumption of thalidomide in early pregnancy was very common in the 1960s, as an antiemetic to control 
morning sickness1. The lack of awareness about the teratogenic properties of the drug led to the birth of ten thou-
sand babies around the world affected by Thalidomide Embryopathy (TE). TE is a condition mainly characterized 
by limb defects1 which occur in 79–89% of the affected individuals2. Other organs frequently affected are the eyes, 
ears and heart1,3, occurring together with limb defects in around 19% of cases2. Severe internal organ defects 
were also diagnosed at the time, although the majority of the children affected by these anomalies died in the 
first years of life3. Nowadays, thalidomide is well known as a potent immunomodulator and antiangiogenic drug, 
properties that have led to its current use in treatment of many types of cancer (especially multiple myeloma) and 
immunological conditions4.
Many aspects of TE have been studied over the past few decades; however, its teratogenic molecular mech-
anism remains to be elucidated. One of the accepted hypotheses is that antiangiogenic property of thalidomide 
inhibits the proper development of new blood vessels, which are essential for limb development2,5.
The importance of nitric oxide in TE development has been reported in experimental studies assessing the ter-
atogenic potential and antiangiogenic property of the drug6–8. Our group has recently published the first molecu-
lar study of TE in humans; we reported that the − 786C (rs2070744) and 894T (rs1799983) alleles – which reduce 
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the expression and activity of the NOS3 gene, respectively, and their derived haplotype – were associated with TE, 
when compared with Brazilian people without congenital anomalies9.
In order to further explore and confirm the role that polymorphic variants in the NOS3 gene result in suscep-
tibility to TE, here we investigated the variable number tandem repeats (VNTR) of intron 4 (rs61722009) in the 
NOS3 gene. Similarly to the previously investigated polymorphisms (− 786T > C and 894G > T), the VNTR 4a/4b 
is common in different populations10. It has an important functional role in regulating eNOS and was believed to 
function either as an enhancer or repressor of NOS3 gene transcription11,12, according to the number of repeats 
present in each allele13.
Results
Sample Characteristics. In total, our study involved 38 Brazilian individuals with TE, born between 1959 
and 2010. The control group was comprised of 136 Brazilian individuals without congenital anomalies, born in 
similar regions and time periods as those TE individuals.
Analysis of Allelic and Genotypic Frequencies. The distribution of all polymorphisms in both the sam-
ple groups was in accordance with the Hardy-Weinberg equilibrium.
Allele and genotype frequencies of the three polymorphisms are listed in Table 1. The frequency of alleles C 
and T in the polymorphism − 786T > C was statistically different between the two sample groups (p = 0.022), 
corroborating results detailed in our previous study with a smaller sample size. However, the intron 4 VNTR and 
the 894G > T polymorphism was not significantly different between the two sample groups.
Linkage Disequilibrium and Haplotype Analysis. Linkage disequilibrium analysis demonstrated that 
the three polymorphisms evaluated are in moderate disequilibrium (D′ > 0.3; p < 0.001).
Haplotypes and their frequencies in the two samples are described in Table 2. A comparison of the haplotype 
frequencies between groups revealed a statistically significant difference (p = 0.007).
Gene Polymorphism Genotype/Allele
Affected Unaffected
P-ValueaN % N %
NOS3 rs2070744 CC 10 26.3 17 12.5 0.060
(C/T) CT 17 44.7 57 41.9
TT 11 28.9 62 45.6
C 37 48.7 91 33.5 0.022
T 39 51.3 181 66.5
rs61722009 4b4b 27 71.1 81 61.8 0.263
(VNTR) 4b4a 11 28.9 41 31.3
4a4a 0 0.0 9 6.9
4b 59 85.5 203 77.5 0.149
4a 11 14.5 59 22.5
rs1799983 TT 5 13.2 13 9.6 0.360
(T/G) TG 21 55.3 63 46.7
GG 12 31.6 59 43.7
T 31 40.8 89 33.0 0.221
G 45 59.2 181 67.0
Table 1. Allelic and genotypic frequencies of the polymorphisms of the NOS3 gene in individuals with 




P-Valuean % n %
NOS3 T 4b G 24 31.6 120 44.1 0.007
T 4b T 9 11.8 30 11.0
T 4a G 6 7.9 30 11.0
T 4a T 0 0.0 1 0.4
C 4b G 10 13.2 6 2.2
C 4b T 22 28.9 56 20.6
C 4a G 5 6.6 26 9.6
C 4a T 0 0.0 3 1.1
Table 2. The inferred haplotypes and haplotypic frequencies in individuals with thalidomide embryopathy, 
as well as in Brazilian individuals without congenital anomalies (unaffected group). aChi-Square Test.
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Evaluation of Risk Allele Association. Univariate logistic regression (Table 3) was performed to 
determine the association of NOS3 with TE susceptibility. The alleles responsible for decrease in NOS3 gene 
expression or eNOS enzyme activity were considered to indicate risk8. Based on this, we divided the sample in 
two groups: (i) individuals with at least one copy of the C, 4b, and T alleles of − 786T > C polymorphism, the 
VNTR, and 894G > T polymorphism, respectively and (ii) individuals without such variants in at least one of the 
polymorphisms.
An association was not identified when all three polymorphisms were present together (p = 0.079). However, 
an analysis of the polymorphism in the promoter region (− 786T > C) and the VNTR (performed in this study) 
showed that compared to the controls, case group showed a higher frequency of the alleles that reduce NOS3 
expression (Odds ratio (OR) = 2.57; 95% IC: 1,20–5,80; p = 0.018) (Table 3).
Discussion
In this study, we have corroborated, using a larger sample size, that the − 786C variant in the promoter region of 
the eNOS gene is more frequently present in individuals affected by TE than in those without congenital abnor-
malities. Moreover, we also identified an interaction between the − 786T > C polymorphism and a functional 
intronic variant, which was previously not analyzed, as a genetic susceptibility factor to TE.
Nitric oxide is responsible for the regulation of vasodilation, exerting its effect through regulating the migra-
tion of endothelial cells6,14. It is also an important pro-angiogenic factor, stimulating the synthesis of cyclic guano-
sine monophosphate (cGMP) through soluble guanylyl-cyclase (sGC) activation7. Experimental models utilizing 
thalidomide and nitric oxide are well established in literature, and have helped to understand the physiological 
actions of nitric oxide in presence or absence of a highly anti-angiogenic teratogen. A previous study has demon-
strated the relevance of nitric oxide in teratogenesis, especially during induction of limb reduction defects in 
mice models15. In addition, a role for nitric oxide in TE development has been suggested in thalidomide experi-
mental models6–8. Thalidomide appears to attenuate nitric-oxide-induced migration of endothelial cells through 
suppression of cGMP levels, inhibiting angiogenesis at a cellular level through interaction with sGC6–8. It has not 
been determined whether a polymorphic eNOS protein would respond differently to the downstream effects of 
sGC-thalidomide interaction, and what consequences this polymorphic protein might have in terms of intensify-
ing or decreasing the teratogenic potential of thalidomide. Nonetheless, it has been demonstrated that nitric oxide 
is able to rescue thalidomide induced teratogenicity in chicken and zebrafish embryos, reinforcing vasculogenesis 
and blocking apoptosis through modulating redox levels8.
Thalidomide is known as a multi-target drug with different therapeutic proprieties. It is not known whether 
these therapeutic proprieties overlap with its teratogenic ones. Anti-inflammatory actions of thalidomide occur 
mainly through the reduction of TNF-alpha mRNA levels16. TNF-alpha is a pro-inflammatory cytokine, stim-
ulated by nuclear factor kappa-B (NF-KB), that able to reduce the half-life of eNOS mRNA17. NF-KB activates 
TNF-alpha to increase the expression of inducible oxide nitric synthase (iNOS) during inflammatory processes18. 
Thus, iNOS is principally responsible for high level of nitric oxide seen during inflammatory reactions, while 
eNOS has little activity in this context19. Overall, eNOS plays a fundamental role during limb outgrowth in the 
context of angiogenesis, while iNOS is irrelevant.
In regards to the effect of thalidomide upon oxidative stress, ROS levels are increased on drug exposure lead-
ing to a misbalance in the NF-KB pathway20. The consequences of this effect on NF-KB, its control of TNF-alpha, 
iNOS activation and eNOS repression remain unknown. Nonetheless, the high levels of ROS generated by thalid-
omide are also suggested to contribute to the drug’s teratogenic effect. Thus, it is possible that for carriers of alleles 
with reduced production of NO, the risks are not only for altered angiogenesis as well as for increased oxidative 
stress (due to thalidomide effect per se) causing synergistic effect susceptibility. Clearly these hypotheses should 
be further tested by in vitro and in vivo assays. As a complicating factor in this scenario, thalidomide is well known 
as an immunomodulatory drug, acting on interleukin (IL) and cytokines levels20. Hence, an individual’s response 
to thalidomide will also depend on their immunological status and developmental stage. Taking all this together, 
we believe that the role played by eNOS during thalidomide teratogenesis could be through multiple functions.
The fact that thalidomide is non-teratogenic in mouse and rats21, highlights the need of molecular studies 
in humans in order for us to fully understand the species-specific teratogenic properties of thalidomide. It has 
been reported that a human’s capacity of responding to an angiogenic stimulus is affected by genetic variants22, 
reflecting a variable susceptibility to develop a disease. The extent of thalidomide-induced teratogenesis is also 
dependent on genetic variability, and so must be considered in the context of TE.
As described in Fig. 1, experimental evidence suggests that the 894G > T polymorphism influences eNOS 
enzyme activity, altering production of nitric oxide25. On the other hand, the 786T > C polymorphism and the 
4a/4b VNTR have been observed to regulate nitric oxide activity at the level of gene expression24,26. Absence of 
interactions between the 894G > T polymorphism and the two other polymorphisms in our univariate logistic 
regression model appears to indicate that thalidomide regulates NOS3 at a pre-transcriptional level; this needs to 
Risk Alleles of NOS3 Gene
Presence Absence
Odds Ratio (95% IC) P-Valuen % n %
(− 786)C + (VNTR)4b 91 53.8 78 46.2 2.570 (1,20–5,80) 0.018
(− 786)C + (VNTR)4b + (894)T 68 52.6 101 36.6 1.921 (0,93–4,01) 0.079
Table 3. Univariate logistic regression model to assess risk alleles in individuals with thalidomide 
embryopathy and in individuals of the unaffected group. CI: confidence interval; Polymorphisms used in the 
model are rs2070744 (− 786C), rs61722009 (VNTR), and rs1799983 (894T).
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be further investigated in studies evaluating additional gene regulation mechanisms. Regardless, the presence of 
alleles that result in reduced NOS3 expression in thalidomide-affected individuals, as well as in other members 
of the population, results in a higher risk of developing the cited vascular conditions. The haplotype C/4b/T 
has previously been associated with lower levels of circulating nitric oxide27; many studies report C/4b/T as the 
susceptibility haplotype to conditions with impaired vascular function, such as hypertension28,29, preeclampsia30, 
and cardiomyopathies31.
Furthermore, the 27pb VNTR, at intron 4 of the NOS3 gene, plays an important role in controlling NOS3 
gene expression. It is responsible for producing microRNA capable of altering DNA methylation and histone 
acetylation in the promoter region of the NOS3 gene, and in regions adjacent to the VNTR itself23,24. It is believed 
that alleles with larger repeats, such as 4b, produce more microRNAs, therefore resulting in reduced NOS3 gene 
expression compared to 4a13. The polymorphism 894G > T has been previously associated with congenital heart 
defects (CHD), especially when together with tobacco exposure in pregnancy33. Recent research has evaluated 
this polymorphism, with − 786C > T in a Chinese sample, although an association was not identified34. In our 
study, it was not possible to determine an association between NOS3 risk haplotypes and congenital anomalies 
(data not showed), possibly due to the evaluated sample size”.
It was reported in the 1960’s that TE occurs in 10–50% of all babies exposed to thalidomide in utero32. Genetic 
variability may help to explain why some individuals are apparently resistant to the drug’s teratogenic effects 
while others are more susceptible. The best approach in a case-control study would be to access people who were 
exposed to thalidomide, although did not develop TE, as a control group. Unfortunately, such data does not exist 
since the thalidomide tragedy occurred more than fifty years ago and unaffected individuals were not identified at 
the time. The control group in the current study is composed of individuals born at the same time as individuals 
affected with TE and in the same Brazilian regions. In these regions, thalidomide was highly available and could 
be bought without prescription. However, it is not possible to confirm if any individuals in the control group were 
exposed to the drug. Clearly, not only this variable was lost, but many other variables needed to evaluate suscep-
tibility or phenotypes characteristic of individuals affected by TE.
In the present study we suggest that individuals with alleles − 786C and (VNTR) 4b may be more sensitive 
to thalidomide than those without these variants. This may help to explain why some individuals were exposed 
to thalidomide but did not develop TE. Further analysis with a larger sample size should help evaluate endophe-
notypes of TE and vascular conditions in both groups. Studies focusing on thalidomide-induced susceptibility 
to embryopathy in angiogenesis (as well as in other pathways) might help elucidate the molecular mechanisms 
Figure 1. Pre-transcriptional and post translational effects of polymorphisms rs2070744, VNTR in intron 
4 (rs61722009) and rs1799983. 
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underlying thalidomide teratogenesis. This may contribute to our understanding and treatment of diseases in 
which these alleles are also considered risk factors. The alleles investigated have high frequency across different 
populations (− 786C varying from 12–44%, and VNTR 4a with a 12–20% frequency)10. Hence, it is also relevant 
to look at presented results with focus and view on personalized medicine strategies. Pharmacogenetic studies, 
especially in Erithema Nodosum Leprosum and Multiple Myeloma (the main conditions treated by thalidomide 
and its analogues), can help not only to identify genetic profiles with a better response to the drug, but also to 
look for alternative drugs when the therapeutic benefits of thalidomide are not reached for these people. Further, 
in vitro and in vivo research is essential to understand the role of the NOS3 polymorphisms analyzed in thalido-
mide teratogenesis as well as in therapeutics settings and pharmacogenetics approaches. We believe this is a first 
step that can put forward different therapeutic strategies involving thalidomide.
Materials and Methods
Ethical Aspects. This study was approved by the Research Ethics Committee of the Clinical Hospital of Porto 
Alegre (number 10-0244). The methods were carried out in accordance with the approved guidelines.
Recruitment and Sample Collection. Individuals with TE were recruited through the Brazilian 
Association of People with Thalidomide Syndrome; all subjects signed the informed consent. The congenital 
anomalies in these individuals were assessed through the TE diagnostic guideline previously published9. Only 
individuals displaying phenotypes compatible with TE were included in this study. Twenty-eight individuals 
completed a clinical questionnaire that characterized their congenital anomalies according to organs and systems 
affected35.
Saliva collection was performed through Oragene-DNA OG-500 (DNA Genotek® ) and DNA was obtained 
according to the manufacturer’s instructions.
The control group consisted of Brazilians without any congenital anomalies. DNA samples from the control 
subjects were stored in the Genetics Department of our institution; they have already been used in previous 
epidemiological studies36,37. Gender, age, date, and place of birth information were also collected from subjects.
SNPs and VNTR Genotyping. The 27bp VNTR of intron 4 (rs61722009) was genotyped according 
to Marroni38. A small percentage (10%) of the sample was selected randomly to confirm the result by Sanger 
sequencing in equipment ABI 3730XL (Applied Biosystems® ).
The polymorphisms rs2070744 and rs1799983 (− 786T > C and 894G > T, respectively) were also geno-
typed in the new cases and controls; these samples were genotyped by TaqMan® Genotyping Assay (Applied 
Biosystems) as previously described39.
Evaluation of Linkage Disequilibrium and Haplotypes. Linkage disequilibrium between variants 
was estimated using the MLocus program40, and the haplotypes were derived using the PHASE v.2.1 software 
(University of Chicago, Chicago, IL, USA).
Statistical Analysis. All statistical analyses were evaluated in SPSS® program, version 20 (SPSS, IBM, USA). 
All tests were two-tailed and the Bonferroni correction was applied in all sample groups.
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